CoChat

Reduced striatal dopamine synthesis capacity in patients with schizophrenia during remission of positive symptoms

Avram, Mihai, Brandl, Felix, Cabello, Jorge, Leucht, Claudia, Scherr, Martin, Mustafa, Mona, Leucht, Stefan, Ziegler, Sibylle, Sorg, Christian · 2019 · Brain
Cited by 70

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

While there is consistent evidence for increased presynaptic dopamine synthesis capacity in the striatum of patients with schizophrenia during psychosis, it is unclear whether this also holds for patients during psychotic remission. This study investigates whether striatal dopamine synthesis capacity is altered in patients with schizophrenia during symptomatic remission of positive symptoms, and whether potential alterations relate to symptoms other than positive, such as cognitive difficulties. Twenty-three patients with schizophrenia in symptomatic remission of positive symptoms according to Andreasen, and 24 healthy controls underwent 18F-DOPA-PET and behavioural-cognitive assessment. Imaging data were analysed with voxel-wise Patlak modelling with cerebellum as reference region, resulting in the influx constant kicer reflecting dopamine synthesis capacity. For the whole striatum and its subdivisions (i.e. limbic, associative, and sensorimotor), averaged regional kicer values were calculated, compared across groups, and correlated with behavioural-cognitive scores, including a mediation analysis. Patients had negative symptoms (Positive and Negative Syndrome Scale-negative 14.13 ± 5.91) and cognitive difficulties, i.e. they performed worse than controls in Trail-Making-Test-B (TMT-B; P = 0.01). Furthermore, kicer was reduced in patients for whole striatum (P = 0.004) and associative (P = 0.002) and sensorimotor subdivisions (P = 0.007). In patients, whole striatum kicer was negatively correlated with TMT-B (rho = -0.42, P = 0.04; i.e. the lower striatal kicer, the worse the cognitive performance). Mediation analysis showed that striatal kicer mediated the group difference in TMT-B. Results demonstrate that patients with schizophrenia in symptomatic remission of positive symptoms have decreased striatal dopamine synthesis capacity, which mediates the disorder's impact on cognitive difficulties. Data suggest that striatal dopamine dysfunction contributes to cognitive difficulties in schizophrenia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awz093

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Research works printed but not linked: 70

  1. Abi-Dargham, 1998, Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort, Am J Psychiatry, 155, 761
  2. Alexander, 1986, Parallel organization of functionally segregated circuits linking basal ganglia and cortex, Ann Rev Neurosci, 9, 357, 10.1146/annurev.ne.09.030186.002041 · DOI · Paper page
  3. Allen, 2008, Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database, Nat Genet, 40, 827, 10.1038/ng.171 · DOI · Paper page
  4. Andreasen, 2005, Remission in schizophrenia: proposed criteria and rationale for consensus, Am J Psychiatry, 162, 441, 10.1176/appi.ajp.162.3.441 · DOI · Paper page
  5. Arbuthnott, 2000, Executive control in set switching: residual switch cost and task-set inhibition, Can J Exp Psychol, 54, 33, 10.1037/h0087328 · DOI · Paper page
  6. Ashok, 2017, The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment, Mol Psychiatry, 22, 666, 10.1038/mp.2017.16 · DOI · Paper page
  7. Avram, 2018, Cortico-thalamic hypo- and hyperconnectivity extend consistently to basal ganglia in schizophrenia, Neuropsychopharmacology, 43, 2239, 10.1038/s41386-018-0059-z · DOI
  8. Beaulieu, 2004, Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade, Proc Natl Acad Sci USA, 101, 5099, 10.1073/pnas.0307921101 · DOI · Paper page
  9. Benarroch, 2016, Intrinsic circuits of the striatum: complexity and clinical correlations, Neurology, 86, 1531, 10.1212/WNL.0000000000002599 · DOI
  10. Berggren, 1985, The effect of acute lithium administration on brain monoamine synthesis and the precursor amino acids tyrosine and tryptophan in brain and plasma in rats, J Neural Transm, 61, 175, 10.1007/BF01251911 · DOI
  11. Berry, 2016, Aging affects dopaminergic neural mechanisms of cognitive flexibility, J Neurosci, 36, 12559, 10.1523/JNEUROSCI.0626-16.2016 · DOI · Paper page
  12. Berry, 2018, The influence of dopamine on cognitive flexibility is mediated by functional connectivity in young but not older adults, J Cogn Neurosci, 30, 1330, 10.1162/jocn_a_01286 · DOI
  13. Bloomfield, 2014, Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms, Biol Psychiatry, 75, 470, 10.1016/j.biopsych.2013.05.027 · DOI · Paper page
  14. Bongiovanni, 2008, Tyrosine depletion lowers dopamine synthesis and desipramine-induced prefrontal cortex catecholamine levels, Brain Res, 1190, 39, 10.1016/j.brainres.2007.10.079 · DOI
  15. Carlsson, 1978, Antipsychotic drugs, neurotransmitters, and schizophrenia, Am J Psychiatry, 135, 165, 10.1176/ajp.135.2.164 · DOI · Paper page
  16. Chen, 2006, Trait vs. state markers for schizophrenia: identification and characterization through visual processes, Curr Psychiatry Rev, 2, 431, 10.2174/157340006778699729 · DOI · Paper page
  17. Cirillo, 2003, Verbal declarative memory dysfunction in schizophrenia: from clinical assessment to genetics and brain mechanisms, Neuropsychol Rev, 13, 43, 10.1023/A:1023870821631 · DOI · Paper page
  18. Cropley, 2008, Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [C-11]NNC 112 and [F-18]FDOPA, Psychiat Res-Neuroim, 163, 171, 10.1016/j.pscychresns.2007.11.003 · DOI
  19. Cumming, 1998, Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms, Synapse, 29, 37, 10.1002/(SICI)1098-2396(199805)29:1<37::AID-SYN4>3.0.CO;2-C · DOI · Paper page
  20. Cumming, 1993, Pharmacokinetics of plasma 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine ([18F]Fdopa) in humans, J Cereb Blood Flow Metab, 13, 668, 10.1038/jcbfm.1993.85 · DOI · Paper page
  21. D’Souza, 2012, Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits, Neuropharmacology, 62, 1564, 10.1016/j.neuropharm.2011.01.044 · DOI · Paper page
  22. Demjaha, 2012, Dopamine synthesis capacity in patients with treatment-resistant schizophrenia, Am J Psychiatry, 169, 1203, 10.1176/appi.ajp.2012.12010144 · DOI · Paper page
  23. Deserno, 2015, Ventral striatal dopamine reflects behavioral and neural signatures of model-based control during sequential decision making, Proc Natl Acad Sci USA, 112, 1595, 10.1073/pnas.1417219112 · DOI · Paper page
  24. Diedrichsen, 2009, A probabilistic MR atlas of the human cerebellum, Neuroimage, 46, 39, 10.1016/j.neuroimage.2009.01.045 · DOI · Paper page
  25. Edwards, 2016, Evaluating the dopamine hypothesis of schizophrenia in a large-scale genome-wide association study, Schizophr Res, 176, 136, 10.1016/j.schres.2016.06.016 · DOI · Paper page
  26. Egerton, 2010, The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function, Neuroimage, 50, 524, 10.1016/j.neuroimage.2009.12.058 · DOI · Paper page
  27. Elkashef, 2000, 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography, Psychiatry Res, 100, 1, 10.1016/S0925-4927(00)00064-0 · DOI
  28. First, 2002, Structured clinical interview for DSM-IV-TR Axis I disorders, research version, patient edition (SCID-I/P)
  29. Frankle, 2006, Prefrontal cortical projections to the midbrain in primates: evidence for a sparse connection, Neuropsychopharmacology, 31, 1627, 10.1038/sj.npp.1300990 · DOI
  30. Fusar-Poli, 2013, Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11)C]-DOPA PET studies, Schizophr Bull, 39, 33, 10.1093/schbul/sbr180 · DOI · Paper page
  31. Gardner, 2010, International consensus study of antipsychotic dosing, Am J Psychiatry, 167, 686, 10.1176/appi.ajp.2009.09060802 · DOI · Paper page
  32. Grunder, 2003, Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo, Neuropsychopharmacology, 28, 787, 10.1038/sj.npp.1300103 · DOI
  33. Hartvig, 1991, Brain kinetics of L-[beta-11C]dopa in humans studied by positron emission tomography, J Neural Transm Gen Sect, 86, 25, 10.1007/BF01250373 · DOI
  34. Hayes, 2013, Introduction to mediation, moderation, and conditional process analysis: a regression-based approach
  35. Hietala, 1999, Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia, Schizophr Res, 35, 41, 10.1016/S0920-9964(98)00113-3 · DOI · Paper page
  36. Hietala, 1995, Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients, Lancet, 346, 1130, 10.1016/S0140-6736(95)91801-9 · DOI · Paper page
  37. Hoffman, 1992, The effects of carbidopa administration on 6-[18F]fluoro-L-dopa kinetics in positron emission tomography, J Nucl Med, 33, 1472
  38. Howes, 2012, The nature of dopamine dysfunction in schizophrenia and what this means for treatment, Arch Gen Psychiatry, 69, 776, 10.1001/archgenpsychiatry.2012.169 · DOI · Paper page
  39. Howes, 2014, Schizophrenia: an integrated sociodevelopmental-cognitive model, Lancet, 383, 1677, 10.1016/S0140-6736(13)62036-X · DOI · Paper page
  40. Karrer, 2017, Reduced dopamine receptors and transporters but not synthesis capacity in normal aging adults: a meta-analysis, Neurobiol Aging, 57, 36, 10.1016/j.neurobiolaging.2017.05.006 · DOI · Paper page
  41. Kay, 1987, The positive and negative syndrome scale (PANSS) for schizophrenia, Schizophr Bull, 13, 261, 10.1093/schbul/13.2.261 · DOI · Paper page
  42. Keefe, 2007, Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial, Arch Gen Psychiatry, 64, 633, 10.1001/archpsyc.64.6.633 · DOI · Paper page
  43. Kienast, 2013, Dopamine-modulated aversive emotion processing fails in alcohol-dependent patients, Pharmacopsychiatry, 46, 130, 10.1055/s-0032-1331747 · DOI
  44. Kim, 2017, Presynaptic dopamine capacity in patients with treatment-resistant schizophrenia taking clozapine: an [(18)F]DOPA PET study, Neuropsychopharmacology, 42, 941, 10.1038/npp.2016.258 · DOI
  45. Kumakura, 2009, PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches, Neuroscientist, 15, 635, 10.1177/1073858409338217 · DOI · Paper page
  46. Laruelle, 1999, Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies, J Psychopharmacol, 13, 358, 10.1177/026988119901300405 · DOI · Paper page
  47. Lindstrom, 1999, Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET, Biol Psychiatry, 46, 681, 10.1016/S0006-3223(99)00109-2 · DOI · Paper page
  48. Mair, 2002, A double dissociation within striatum between serial reaction time and radial maze delayed nonmatching performance in rats, J Neurosci, 22, 6756, 10.1523/JNEUROSCI.22-15-06756.2002 · DOI · Paper page
  49. Malhi, 2013, Potential mechanisms of action of lithium in bipolar disorder. Current understanding, CNS Drugs, 27, 135, 10.1007/s40263-013-0039-0 · DOI · Paper page
  50. McCutcheon, 2018, Defining the locus of dopaminergic dysfunction in schizophrenia: a meta-analysis and test of the mesolimbic hypothesis, Schizophr Bull, 44, 1301, 10.1093/schbul/sbx180 · DOI · Paper page
  51. McFarlane, 2011, Acute lithium administration selectively lowers tyrosine levels in serum and brain, Brain Res, 1420, 29, 10.1016/j.brainres.2011.08.054 · DOI
  52. McGowan, 2004, Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study, Arch Gen Psychiatry, 61, 134, 10.1001/archpsyc.61.2.134 · DOI · Paper page
  53. Mundt, 1989, The diagnostic specificity of negative symptoms and their psychopathological context, Br J Psychiatry Suppl, 32, 10.1192/S0007125000291447 · doi:10.1192/s0007125000291447
  54. Nozaki, 2009, Regional dopamine synthesis in patients with schizophrenia using L-[beta-11C]DOPA PET, Schizophr Res, 108, 78, 10.1016/j.schres.2008.11.006 · DOI
  55. Okochi, 2009, Meta-analysis of association between genetic variants in COMT and schizophrenia: an update, Schizophr Res, 110, 140, 10.1016/j.schres.2009.02.019 · DOI
  56. Oram, 2005, Executive control of working memory in schizophrenia, Psychiatry Res, 135, 81, 10.1016/j.psychres.2005.03.002 · DOI
  57. Patlak, 1985, Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations, J Cereb Blood Flow Metab, 5, 584, 10.1038/jcbfm.1985.87 · DOI · Paper page
  58. Patlak, 1983, Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data, J Cerebr Blood F Met, 3, 1, 10.1038/jcbfm.1983.1 · DOI · Paper page
  59. Pogarell, 2012, Dopaminergic neurotransmission in patients with schizophrenia in relation to positive and negative symptoms, Pharmacopsychiatry, 45, S36, 10.1055/s-0032-1306313 · DOI · Paper page
  60. Reichenberg, 2010, The assessment of neuropsychological functioning in schizophrenia, Dialogues Clin Neurosci, 12, 383, 10.31887/DCNS.2010.12.3/areichenberg · DOI · Paper page
  61. Salthouse, 2011, What cognitive abilities are involved in trail-making performance?, Intelligence, 39, 222, 10.1016/j.intell.2011.03.001 · DOI · Paper page
  62. Schabram, 2014, Acute and sustained effects of methylphenidate on cognition and presynaptic dopamine metabolism: an [18F]FDOPA PET study, J Neurosci, 34, 14769, 10.1523/JNEUROSCI.1560-14.2014 · DOI
  63. Sesack, 2002, Synaptology of dopamine neurons, 10.1007/978-3-642-56051-4_4 · DOI
  64. Shotbolt, 2011, Striatal dopamine synthesis capacity in twins discordant for schizophrenia, Psychol Med, 41, 2331, 10.1017/S0033291711000341 · DOI · Paper page
  65. Thompson, 2013, Striatal dopamine release in schizophrenia comorbid with substance dependence, Mol Psychiatry, 18, 909, 10.1038/mp.2012.109 · DOI
  66. Tunbridge, 2006, Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond, Biol Psychiatry, 60, 141, 10.1016/j.biopsych.2005.10.024 · DOI · Paper page
  67. van Rossum, 1966, The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs, Arch Int Pharmacodyn Ther, 160, 492
  68. Vernaleken, 2007, ‘Prefrontal’ cognitive performance of healthy subjects positively correlates with cerebral FDOPA influx: an exploratory [18F]-fluoro-L-DOPA-PET investigation, Hum Brain Mapp, 28, 931, 10.1002/hbm.20325 · DOI · Paper page
  69. Weinstein, 2017, Pathway-Specific Dopamine Abnormalities in Schizophrenia, Biol Psychiatry, 81, 31, 10.1016/j.biopsych.2016.03.2104 · DOI · Paper page
  70. Wils, 2017, Antipsychotic medication and remission of psychotic symptoms 10years after a first-episode psychosis, Schizophr Res, 182, 42, 10.1016/j.schres.2016.10.030 · DOI

Cited by

See all 70

Metadata

Authors
Avram, M., Brandl, F., Cabello, J., Leucht, C., Scherr, M., Mustafa, M., Leucht, S., Ziegler, S., & Sorg, C.
Venue
Brain
Published
2019-04-26
Volume
142
Issue
6
Pages
1813-1826
ISSN
  • 0006-8950
  • 1460-2156
Cited by
70
References
31
Language
en
Funders
  • European Union 7th Framework Programme
  • TRIMAGE (602621)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reduced striatal dopamine synthesis capacity in patients with schizophrenia during remission of positive symptoms. https://app.cochat.ai/papers/10.1093/brain/awz093
The paper
Avram, M., Brandl, F., Cabello, J., Leucht, C., Scherr, M., Mustafa, M., Leucht, S., Ziegler, S., & Sorg, C. (2019). Reduced striatal dopamine synthesis capacity in patients with schizophrenia during remission of positive symptoms. Brain. https://doi.org/10.1093/brain/awz093

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.